Table 2.

Subgroup analysis stratified by gender and smoking status

SNP	Case			Control			Ptrenda	OR (95% CI) b	Phetc
	AA	AG	GG	AA	AG	GG
rs11543198
Male	16	148	427	309	2220	3876	3.01 × 10−8	1.58 (1.34–1.87)	0.07
Female	6	45	97	229	1697	3049	0.32	1.16 (0.86–1.55)
Smoker	11	95	294	295	2101	3714	8.63 × 10−7	1.65 (1.34–1.87)	0.10
Nonsmoker	11	98	230	243	1816	3211	0.01	1.30 (0.86–1.55)
Male/smoker	10	90	281	218	1579	2816	1.63 × 10−6	1.66 (1.35–2.04)	0.15
Male/nonsmoker	6	58	146	91	641	1060	3.24 × 10−3	1.49 (1.14–1.95)
Female/smoker	1	5	13	77	522	898	0.54	1.29 (0.57–2.95)
Female/nonsmoker	5	40	84	152	1175	2151	0.47	1.12 (0.82–1.54)

A total of 739 bladder cancer cases and 11 380 controls were analyzed.

^aP-value obtained from Cochrane–Armitage trend test.

^bORs and CI are calculated using the non-susceptible allele (A) as reference.

^cThe P-value of heterogeneities across four subgroups was examined by using the Breslow–Day test.